MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In






New Ovarian Cancer Treatment Succeeds in Lab

Nanoparticles deliver paclitaxel to tumors (October 16)

In a study published in Scientific Reports, researchers at Florida International University describe what could be a breakthrough in the treatment of ovarian cancer: a new way to deliver cancer-killing drugs using nanotechnology.

In laboratory experiments, paclitaxel (Taxol, Bristol-Myers Squibb), a chemotherapy drug used to treat ovarian cancer, was loaded onto a magneto-electric nanoparticle. Aided by an electric field, the drug was able to penetrate tumor cells, destroying the tumor within 24 hours while sparing normal ovarian cells.

“Sparing healthy cells has been a major challenge in the treatment of cancer, especially with the use of Taxol; so in addition to treating the cancer, this could have a huge impact on side effects and toxicity,” said Carolyn Runowicz, MD.

Ovarian cancer is the deadliest of all gynecologic cancers. According to the American Cancer Society, 14,000 women will die this year from the disease.

Source: Florida International University; October 16, 2013.

More stories